JP2021526525A5 - - Google Patents
Info
- Publication number
- JP2021526525A5 JP2021526525A5 JP2020566845A JP2020566845A JP2021526525A5 JP 2021526525 A5 JP2021526525 A5 JP 2021526525A5 JP 2020566845 A JP2020566845 A JP 2020566845A JP 2020566845 A JP2020566845 A JP 2020566845A JP 2021526525 A5 JP2021526525 A5 JP 2021526525A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- adc
- here
- patient
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024095931A JP2024154433A (ja) | 2018-06-07 | 2024-06-13 | 抗体薬物コンジュゲート(adcs)を用いた治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682154P | 2018-06-07 | 2018-06-07 | |
| US62/682,154 | 2018-06-07 | ||
| US201962841702P | 2019-05-01 | 2019-05-01 | |
| US62/841,702 | 2019-05-01 | ||
| PCT/IB2019/054748 WO2019234694A2 (en) | 2018-06-07 | 2019-06-07 | Therapeutic methods using antibody drug conjugates (adcs) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024095931A Division JP2024154433A (ja) | 2018-06-07 | 2024-06-13 | 抗体薬物コンジュゲート(adcs)を用いた治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021526525A JP2021526525A (ja) | 2021-10-07 |
| JP2021526525A5 true JP2021526525A5 (cg-RX-API-DMAC7.html) | 2022-06-14 |
Family
ID=68769968
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566845A Pending JP2021526525A (ja) | 2018-06-07 | 2019-06-07 | 抗体薬物コンジュゲート(adcs)を用いた治療方法 |
| JP2024095931A Pending JP2024154433A (ja) | 2018-06-07 | 2024-06-13 | 抗体薬物コンジュゲート(adcs)を用いた治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024095931A Pending JP2024154433A (ja) | 2018-06-07 | 2024-06-13 | 抗体薬物コンジュゲート(adcs)を用いた治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210283267A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3801635A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021526525A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112566671A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019283654A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3101943A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019234694A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| JP2022529727A (ja) * | 2019-04-24 | 2022-06-23 | マジェンタ セラピューティクス インコーポレイテッド | Anti-cd117 とその使用 |
| WO2020219778A2 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd117 antibody-drug conjugates and uses thereof |
| JP2022530442A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | アントラサイクリン抗体薬物複合体およびその使用 |
| JP2022530438A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | 抗cd117抗体薬物複合体およびその使用 |
| GB202004263D0 (en) * | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080080482A (ko) * | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 eph 수용체 항체 |
| PL2099823T5 (pl) * | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| AR086044A1 (es) * | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| ES2945588T3 (es) * | 2014-08-26 | 2023-07-04 | Univ Leland Stanford Junior | Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora |
| ES2826566T3 (es) * | 2014-11-21 | 2021-05-18 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas |
| HK1256681A1 (zh) * | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| AU2016258988A1 (en) * | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
| EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| US10464969B2 (en) * | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
| US10111966B2 (en) * | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
| CN117653740A (zh) * | 2016-12-21 | 2024-03-08 | 诺华股份有限公司 | 用于消融造血干细胞的抗体药物缀合物 |
| JP2020519640A (ja) * | 2017-05-17 | 2020-07-02 | イミュノジェン, インコーポレイテッド | 抗cd33イムノコンジュゲート投与計画 |
-
2019
- 2019-06-07 JP JP2020566845A patent/JP2021526525A/ja active Pending
- 2019-06-07 AU AU2019283654A patent/AU2019283654A1/en not_active Abandoned
- 2019-06-07 EP EP19815485.8A patent/EP3801635A4/en active Pending
- 2019-06-07 CN CN201980052505.3A patent/CN112566671A/zh active Pending
- 2019-06-07 CA CA3101943A patent/CA3101943A1/en active Pending
- 2019-06-07 WO PCT/IB2019/054748 patent/WO2019234694A2/en not_active Ceased
-
2020
- 2020-12-04 US US17/111,816 patent/US20210283267A1/en not_active Abandoned
-
2024
- 2024-06-13 JP JP2024095931A patent/JP2024154433A/ja active Pending
-
2025
- 2025-02-28 US US19/067,310 patent/US20260014202A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021225125B9 (en) | Antibody drug conjugate loaded with binary toxins and its application | |
| AU2019455069B2 (en) | A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers | |
| JP5314590B2 (ja) | カンプトテシン結合部分 | |
| ES2941520T3 (es) | Compuestos de 1H-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (TLR7) y métodos y usos para los mismos | |
| TWI362934B (en) | Phosphonate analogs of hiv inhibitor compounds | |
| JP2020506176A5 (cg-RX-API-DMAC7.html) | ||
| US20230295346A1 (en) | Prodruggable antibodies, prodrugs thereof, and methods of use and making | |
| JP2022512778A5 (cg-RX-API-DMAC7.html) | ||
| HUE027549T2 (hu) | Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére | |
| KR20220147719A (ko) | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 | |
| JP2010516675A (ja) | 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分 | |
| JP2018509394A5 (cg-RX-API-DMAC7.html) | ||
| CA3253667A1 (en) | ANTIBODY-DRUG CONJUGATE, RELATED PHARMACEUTICAL COMPOSITION AND RELATED USE | |
| RS62860B1 (sr) | Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih | |
| CN117157098A (zh) | 一种药物组合及其用途 | |
| US20230181743A1 (en) | Functional lipid derivatives and uses thereof | |
| TW202432559A (zh) | 一類連接子藥物及其抗體-藥物偶聯物的製備方法和應用 | |
| Takeuchi et al. | Effects of bleomycin on mouse transplantable tumors | |
| EA022408B1 (ru) | Производные санглиферина и способы их получения | |
| CN1817866A (zh) | 一组连有核苷碱基的格尔德霉素衍生物 | |
| WO2000067792A1 (fr) | Anticorps monoclonal dirige contre les cellules de carcinome renal humain | |
| CN115944629A (zh) | 雷帕霉素在治疗或预防乙型肝炎中的应用 | |
| US11717540B2 (en) | Modified immune cells and uses thereof | |
| RU2795148C2 (ru) | Конъюгат антитело-лекарственное средство, нагруженный бинарными токсинами, и его применение | |
| HK40085783A (en) | Antibody drug conjugate loaded with double toxins and application thereof |